Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PTPRA | P18433 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30925300 | 1.00 | CYP1A2 (0.57) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 | |
| SCHEMBL11074830 | 0.87 | CYP1A2 (0.56) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 | |
| SCHEMBL3239462 | 0.81 | CYP1A2 (0.52) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 | |
| SCHEMBL10759826 | 0.80 | CYP1A2 (0.49) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 | |
| SCHEMBL8503990 | 0.80 | CYP1A2 (0.70) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 | |
| SCHEMBL6532240 | 0.77 | CYP1A2 (0.58) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 | |
| SCHEMBL7206606 | 0.76 | CYP1A2 (0.56) | CYP1A2SMN1; SMN2CYP2C19RAB9ALMNA | |
| SCHEMBL116939 | 0.75 | CYP1A2 (0.58) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 | |
| SCHEMBL30195799 | 0.75 | CYP1A2 (0.58) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 | |
| SCHEMBL27461429 | 0.74 | CYP1A2 (0.55) | CYP1A2SMN1; SMN2CYP2C19RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133039-B2 | Kinase inhibitor compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-09-15 | — | — | US | claimed |
| US-8367078-B2 | Kinase inhibitor compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-02-05 | — | — | US | claimed |
| WO-2011109217-A2 | METHODS OF TREATING OR PREVENTING RNA POLYMERASE DEPENDENT VIRAL DISORDERS BY ADMINISTRATION OF JAK2 KINASE INHIBITORS | IMMUNODIAGNOSTICS, INC. (US) | 2011-09-09 | — | — | WO | claimed |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS, INC. (US) | 2025-12-25 | — | — | US | disclosed |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | KARTOS THERAPEUTICS, INC. (US) | 2025-04-08 | — | — | US | disclosed |
| WO-2024124240-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | KARTOS THERAPEUTICS (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-3803402-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2023-04-26 | — | — | EP | disclosed |
| US-20220054472-A1 | Methods of Treating Myeloproliferative Neoplasms | KARTOS THERAPEUTICS INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3578981-B1 | ANTI-CANCER TREATMENT OF PRESELECTED SUBJECTS AND SCREENING METHODS TO IDENTIFY SUSCEPTIBLE SUBJECTS | TUDAG TU DRESDEN AG (DE) | 2021-10-27 | — | — | EP | disclosed |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2021-08-19 | — | — | US | disclosed |
| US-9133039-B2 | Kinase inhibitor compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2015-07-02 | — | — | US | disclosed |
| EP-2872161-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | Del Mar Pharmaceuticals (CA) | 2015-05-20 | — | — | EP | disclosed |
| US-20140193518-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2014-07-10 | — | — | US | disclosed |
| WO-2014004376-A2 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | DEL MAR PHARMACEUTICALS (CA) | 2014-01-03 | — | — | WO | disclosed |
| US-8367078-B2 | Kinase inhibitor compounds | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| WO-2011109217-A2 | METHODS OF TREATING OR PREVENTING RNA POLYMERASE DEPENDENT VIRAL DISORDERS BY ADMINISTRATION OF JAK2 KINASE INHIBITORS | IMMUNODIAGNOSTICS, INC. (US) | 2011-09-09 | — | — | WO | disclosed |
| US-20100278933-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC (US) | 2010-11-04 | — | — | US | disclosed |
| WO-2008153900-A1 | KINASE INHIBITOR COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100278933-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K2, MAP3K6 | CYP1A2 2306/4885SMN1; SMN2 3924/4885CYP2C19 2607/4885 |
| US-20250387383-A1 | METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS | JAK2, JAK1, MPL | CYP1A2 2351/4885SMN1; SMN2 605/4885CYP2C19 2419/4885 |
| US-20220054472-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, JAK1, PDPK1 | CYP1A2 1459/4885SMN1; SMN2 1510/4885CYP2C19 1775/4885 |
| US-20140193518-A1 | KINASE INHIBITOR COMPOUNDS | MAP3K1, MAP3K2, MAP3K6 | CYP1A2 2306/4885SMN1; SMN2 3924/4885CYP2C19 2607/4885 |
| US-20150182490-A1 | METHODS FOR TREATING TYROSINE-KINASE-INHIBITOR-RESISTANT MALIGNANCIES IN PATIENTS WITH GENETIC POLYMORPHISMS OR AHI1 DYSREGULATIONS OR MUTATIONS EMPLOYING DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL, DIBROMODULCITOL, OR ANALOGS OR DERIVATIVES THEREOF | WHR1, AIPL1, TDP1 | CYP1A2 4534/4885SMN1; SMN2 3505/4885CYP2C19 4619/4885 |
| US-12268681-B2 | Methods of treating myeloproliferative neoplasms | JAK2, JAK1, PDPK1 | CYP1A2 1459/4885SMN1; SMN2 1510/4885CYP2C19 1775/4885 |
| US-20210251944-A1 | METHODS FOR TREATING A CANCER RESISTANT TO AT LEAST ONE TYROSINE KINASE INHIBITOR | DCLRE1B, AIPL1, WHR1 | CYP1A2 4656/4885SMN1; SMN2 3557/4885CYP2C19 4731/4885 |
| US-20260097028-A1 | Methods of Treating Myeloproliferative Neoplasms | JAK2, TP53, CDKN1A | CYP1A2 3549/4885SMN1; SMN2 1272/4885CYP2C19 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.